Regencell Bioscience [RGC] vs Haleon Plc - ADR [HLN] Detailed Stock Comparison

Regencell Bioscience Holdings Ltd.

NASDAQ
Loading...

Haleon Plc - ADR

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Regencell Bioscience Holdings Ltd. wins in 2 metrics, Haleon Plc - ADR wins in 13 metrics, with 0 ties. Haleon Plc - ADR appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Regencell Bioscience Holdings Ltd. Haleon Plc - ADR Better
P/E Ratio (TTM) -3,258.62 18.72 Haleon Plc - ADR
Price-to-Book Ratio 2,929.00 1.88 Haleon Plc - ADR
Debt-to-Equity Ratio 11.20 52.37 Regencell Bioscience Holdings Ltd.
PEG Ratio N/A 15.42 N/A
EV/EBITDA -3,921.47 33.08 Haleon Plc - ADR
Profit Margin (TTM) 0.00% 15.11% Haleon Plc - ADR
Operating Margin (TTM) 0.00% 23.17% Haleon Plc - ADR
EBITDA Margin (TTM) N/A 23.17% N/A
Return on Equity -54.81% 10.27% Haleon Plc - ADR
Return on Assets (TTM) -33.20% 4.67% Haleon Plc - ADR
Free Cash Flow (TTM) $-4.01M $2.22B Haleon Plc - ADR
Dividend Yield N/A 1.63% N/A
1-Year Return 20.24% -16.01% Regencell Bioscience Holdings Ltd.
Price-to-Sales Ratio (TTM) N/A 3.78 N/A
Enterprise Value $14.48B $122.54B Haleon Plc - ADR
EV/Revenue Ratio N/A 8.23 N/A
Gross Profit Margin (TTM) N/A 55.38% N/A
Revenue per Share (TTM) $0 $2 Haleon Plc - ADR
Earnings per Share (Diluted) $-0.01 $0.50 Haleon Plc - ADR
Beta (Stock Volatility) 2.25 0.33 Haleon Plc - ADR
Short % of Float 1.26% 0.43% Haleon Plc - ADR

Regencell Bioscience Holdings Ltd. vs Haleon Plc - ADR Stock Performance Analysis

Loading Price Chart...

RGC
HLN

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Regencell Bioscience Holdings Ltd.-9.24%-20.10%-40.20%-24.65%-0.98%-16.80%
Haleon Plc - ADR-0.66%2.02%1.23%-13.29%-7.73%-9.30%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Regencell Bioscience Holdings Ltd.20.24%2,888.89%6,625.00%6,625.00%6,625.00%6,625.00%
Haleon Plc - ADR-16.01%8.43%23.21%23.21%23.21%23.21%

Performance & Financial Health Analysis: Regencell Bioscience Holdings Ltd. vs Haleon Plc - ADR

MetricRGCHLN
Market Information
Market Cap i$14.00B$42.40B
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i105,4786,594,249
90 Day Avg. Volume i162,7437,985,230
Last Close$17.09$9.07
52 Week Range$9.39 - $83.60$8.65 - $11.28
% from 52W High-79.56%-19.59%
All-Time High$950.00 (May 30, 2025)$11.42 (Jun 02, 2025)
% from All-Time High-98.20%-20.58%
Growth Metrics
Quarterly Revenue GrowthN/A0.01%
Quarterly Earnings GrowthN/A0.86%
Financial Health
Profit Margin (TTM) i0.00%0.15%
Operating Margin (TTM) i0.00%0.23%
Return on Equity (TTM) i-0.55%0.10%
Debt to Equity (MRQ) i11.2052.37
Cash & Liquidity
Book Value per Share (MRQ)$0.01$4.99
Cash per Share (MRQ)$0.01$0.15
Operating Cash Flow (TTM) i$-3,113,576$3.56B
Levered Free Cash Flow (TTM) i$-1,507,277$1.89B
Dividends
Last 12-Month Dividend Yield iN/A1.63%
Last 12-Month Dividend iN/A$0.17

Valuation & Enterprise Metrics Analysis: Regencell Bioscience Holdings Ltd. vs Haleon Plc - ADR

MetricRGC (Apr 24, 2026)HLN (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i-3,258.6218.72
Forward P/E iN/A15.42
PEG Ratio iN/A15.42
Price to Sales (TTM) iN/A3.78
Price to Book (MRQ) i2,929.001.88
Market Capitalization
Market Capitalization i$14.00B$42.40B
Enterprise Value i$14.48B$122.54B
Enterprise Value Metrics
Enterprise to Revenue iN/A8.23
Enterprise to EBITDA i-3,921.4733.08
Risk & Other Metrics
Beta i2.250.33
Book Value per Share (MRQ) i$0.01$4.99

Financial Statements Comparison: Regencell Bioscience Holdings Ltd. vs Haleon Plc - ADR

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricRGC (2024)HLN (2025)
Revenue/Sales i011.03B
Cost of Goods Sold iN/A3.95B
COGS % of Revenue i-35.8%
Gross Profit iN/A7.08B
Gross Margin i-64.2%
Research & Development i1.07M316.00M
Operating Income (EBIT) i-4.74M2.41B
Operating Margin i-21.9%
EBITDA i-3.99M2.81B
EBITDA Margin i-25.5%
Pre-Tax Income i-4.36M2.15B
Pre-Tax Income % of Revenue i-19.5%
Income Tax i0472.00M
Income Tax % of Revenue i-4.3%
Net Income (Profit) i-4.36M1.68B
Profit Margin i-15.2%

Balance Sheet & Liquidity Metrics

MetricRGC (2024)HLN (2025)
Cash & Equivalents i2.96M1.26B
Total Current Assets i8.11M4.55B
Total Current Assets % of Revenue i-41.3%
Total Current Liabilities i193,5784.93B
Total Current Liabilities % of Revenue i-44.7%
Long-Term Debt i25,9347.75B
Long-Term Debt % of Revenue i-70.2%
Total Shareholders Equity i8.22M16.48B
Retained Earnings i-21.62M27.85B
Retained Earnings % of Revenue i-252.5%
Property, Plant & Equipment i84,7801.00M

Cash Flow Statement Comparison

MetricRGC (2024)HLN (2025)
Operating Cash Flow i-3.88M2.19B
Operating Cash Flow % of Revenue i-19.8%
Capital Expenditures i-5,376-322.00M
Free Cash Flow i-4.01M2.22B
FCF Margin i-20.1%
Debt Repayment iN/A-1.35B
Common Stock Repurchase iN/A-654.00M

Short Interest & Institutional Ownership Analysis

MetricRGCHLN
Shares Short i700,50919.28M
Short Ratio i5.622.14
Short % of Float i1.26%0.43%
Shares Outstanding i494.49M8.91B
Float Shares i43.94M8.86B
% Held by Insiders i88.56%0.01%
% Held by Institutions i0.12%12.74%
% Held by Public i11.32%87.25%

Dividend Analysis & Yield Comparison: Regencell Bioscience Holdings Ltd. vs Haleon Plc - ADR

MetricRGCHLN
Last 12-Month Dividend iN/A$0.17
Last 12-Month Dividend Yield iN/A1.63%
3-Year Avg Annual Dividend iN/A$0.11
3-Year Avg Dividend Yield iN/A0.91%
3-Year Total Dividends iN/A$0.34
Ex-Dividend DateN/AApr 25, 2025